Is DexCom (DXCM) Overvalued?

Dexcom's stock price has been under pressure, with returns of 6.5% over the last week and 10.0% over the last year. The company's valuation score is 2 out of 6, and a Discounted Cash Flow (DCF) analysis suggests that Dexcom is roughly 1.1% overvalued, with an intrinsic value per share of $63.52. The DCF model is a 2 Stage Free Cash Flow to Equity approach, using cash flows in $ and projecting free cash flow in 2030 to be $1.66b.